HilleVax (HLVX) to Cut 40% Staff

HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced a workforce reduction to reduce its operating expenses. The reduction of approximately 41 employees, or approximately 40% of the company’s workforce, is intended to preserve cash while maintaining core capabilities as the company explores the potential for continued development of its HIL-214 and HIL-216 norovirus vaccine candidates as well as business development-related activities for these vaccine candidates.

You May Also Be Interested In

• lululemon athletica (LULU) call put ratio 1 call to 1 put into quarter results
• UiPath Inc. (PATH) call put ratio 1 call to 2.2 puts into quarter results
• United States Oil Fund (USO) call put ratio 1 call to 1.5 puts as share price up 1.1%